Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): Two Reasons This Biotech Hardly Moved After a Successful Trial
Adding Esperion Therapeutics' ECT-1002 to Pfizer Inc. (NYSE:PFE)'s Lipitor lowered bad LDL cholesterol levels by 22%.
Posts Tagged ‘NASDAQ:AMGN’
Eli Lilly & Co. (LLY), Amgen, Inc. (AMGN), Merck & Co., Inc. (MRK): Where We’re Headed
Over the past couple of months we've discussed many of the biggest risk factors associated with some of the leading causes of death in the United States -- heart disease, cancer...
Amgen, Inc. (AMGN), Astex Pharmaceuticals, Inc. (ASTX), Pharmacyclics, Inc. (PCYC): This Week in Biotech
With the SPDR S&P Biotech Index up 35% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Celgene Corporation (CELG), Cytokinetics, Inc. (CYTK), Astex Pharmaceuticals, Inc. (ASTX): Is the Biotech Bubble About to Burst?
"Bubble" can be a provocative word in investing circles. Think of all that comes to mind when you hear it -- perhaps other words like over-hyped, overvalued, risky, etc.
Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX): Monday’s Best Stocks
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Amgen, Inc. (AMGN), Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Onyx Pharmaceuticals, Inc. (ONXX): This Biotech Envisions Green
After a second offer, Amgen, Inc. (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc.
The Amgen, Inc. (AMGN)-Onyx Pharmaceuticals, Inc. (ONXX) Deal Should Make All Biotech Investors Happy
While that's certainly not what Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) investors were hoping for -- at one point, after Amgen, Inc.
Amgen, Inc. (AMGN), Onyx Pharmaceuticals, Inc. (ONXX), NASDAQ OMX Group, Inc. (NDAQ): Deals, Not Data, Drive Dow Today
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Amgen, Inc. (AMGN): Is Galena Biopharma Inc (GALE)’s Big Break Just Around the Corner?
Judging by the numbers, Galena Biopharma Inc (NASDAQ:GALE) isn't exactly a stock many would call great.
Amgen, Inc. (AMGN) and Onyx Pharmaceuticals, Inc. (ONXX): Half a Billion Dollars’ Worth of Drama
A finale has at last arrived for the biotech drama of summer 2013. Amgen, Inc. (NASDAQ:AMGN) announced yesterday that it will buy Onyx Pharmaceuticals, Inc.
What Is Amgen, Inc. (AMGN) Getting For Its Money?
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing...
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN), Microsoft Corporation (MSFT): Stocks to Watch Closely Today
Since the first day of the week can predict the flow of the whole week, it is particularly crucial to focus on Monday news and events.
Pfizer Inc. (PFE), Amgen, Inc. (AMGN), UnitedHealth Group Inc. (UNH): Do Health Care Stocks Fall in the Fall?
Every investor has heard the old line "sell in May and go away." That wasn't such great advice this year with the S&P 500 index up nearly 5% since the beginning of May.
Hedge Funds Are Buying Amgen, Inc. (AMGN)
To the average investor, there are tons of metrics shareholders can use to analyze stocks. Some of the most innovative are hedge fund and insider trading activity.
Amgen, Inc. (AMGN), AstraZeneca plc (ADR) (AZN): What’s the Big Deal About Onyx Pharmaceuticals, Inc. (ONXX) Anyway?
At the end of June, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced that it had rejected an offer from Amgen, Inc.
This Biogen Idec Inc. (BIIB) Data is Screaming ‘Buy, Buy, Buy’
To many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten age.
Medivation Inc (MDVN), Seattle Genetics, Inc. (SGEN) – Biotech Buyouts: Who’s Next?
There's been plenty of buzz lately about the continuing saga of the possible buyout of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) by Amgen, Inc. (NASDAQ:AMGN).
Pharma News: Vivus, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)’s Settled Stock & Amgen, Inc. (AMGN)’s Clinical Trial
Investors in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) saw new options become available this week, for the April 2014 expiration. ...VIVUS, Inc.
Is Celgene Corporation (CELG) Going to Burn You?
To many traders, hedge funds are perceived as overrated, outdated investment tools of a forgotten age.
Green Mountain Coffee Roasters Inc. (GMCR), Gilead Sciences, Inc. (GILD): Investing in Quality Stocks — Made Easy
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Novartis AG (ADR) (NVS), Amgen, Inc. (AMGN): Incyte Corporation (INCY) Jumps on Jakafi Results
Incyte Corporation (NASDAQ:INCY) today announced positive results from a phase 2 study of its drug Jakafi in treating refractory metastatic pancreatic cancer.
Who’s Betting On Gilead Sciences, Inc. (GILD)?
If you were to ask many investors, hedge funds are seen as delayed, old financial vehicles of an era lost to time.
Pfizer Inc. (PFE), Regeneron Pharmaceuticals Inc (REGN): Are These Drugs the Future of High-Cholesterol Treatment?
Once upon a time in a regulatory environment far, far away, there was a cholesterol-fighting drug named Lipitor from Pfizer Inc. (NYSE:PFE).
Pharma News: VIVUS, Inc. (VVUS)’s Injury, Arena Pharmaceuticals, Inc. (ARNA) & Amgen, Inc. (AMGN)’s Agreement
The ratings of four Pharmaceutical stocks are down this week, according to the Portfolio Grader database.
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN), Alexion Pharmaceuticals, Inc. (ALXN): Biotech’s Falling Fortunes Stymie Osiris Therapeutics, Inc. (OSIR)’s Huge Week
Biotech's the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts...
Pharma News: VIVUS, Inc. (VVUS) Qsymia Patents, Arena Pharmaceuticals, Inc. (ARNA) Earnings, Amgen, Inc. (AMGN) Ending an Agreement
Earlier today RFD IP Business Services ("RFD") released a new report analyzing the likely inequitable conduct challenges to VIVUS, Inc.
Amgen, Inc. (AMGN), Corning Incorporated (GLW): Top Stocks Growing Their Dividends By 25% Per Year
Dividend investors would be wise to focus not just on a stock's current yield, but also on the long-term growth potential of its dividends.
GlaxoSmithKline plc (ADR) (GSK), Roche Holding Ltd. (ADR) (RHHBY): Why Alex Rodriguez Could Bring Big Business to This Sector
Baseball star Alex Rodriguez had an opportunity to be perhaps the greatest player of the past decade or even longer -- that was until he threw it all away by admitting to steroid...
Amgen, Inc. (AMGN), Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): A Closer Look at the Battle Over Cancer Treatments
Over the past year, the battle over cancer treatments has heated up considerably. Big pharma companies such as Amgen, Inc. (NASDAQ:AMGN), Pfizer Inc.
Aegerion Pharmaceuticals, Inc. (AEGR), ISIS Pharmaceuticals, Inc. (ISIS), Sanofi SA (ADR) (SNY): This Is One Incredible CEO
The Motley Fool's readers have spoken, and I have heeded their cries.
Pfizer Inc. (PFE), Amgen, Inc. (AMGN): The Best-Selling Medications of 2013 (So Far)
Believe it or not, 2013 is getting close to being two-thirds of the way over. Many pharmaceutical firms have enjoyed great stock returns and nice profits thus far in the year.
3 Things You Need to Know From Vical Incorporated (VICL)’s Q2 Results
Vical Incorporated (NASDAQ:VICL) announced its second-quarter results on Thursday.
Amgen, Inc. (AMGN), Baxter International Inc. (BAX): Can the FDA Make Up Its Mind Already?
It isn't very often that an agency sometimes accused of over-regulating an industry can be ridiculed for not regulating enough, but that's exactly where the Food and Drug Administration...
Three Things You Need to Know From Keryx Biopharmaceuticals (KERX)’s Q2 Earnings
Keryx Biopharmaceuticals (NASDAQ:KERX) announced its second-quarter results before the market opened on Thursday.
Is More Patent Pain Headed Merck & Co., Inc. (MRK)’s Way?
Merck & Co., Inc. (NYSE:MRK) might be one of big pharma's largest companies, but this health care leader has had a tough go recently.
Pharma News: Vivus, Inc. (VVUS)’s New CEO, Arena Pharmaceuticals, Inc. (ARNA) & Amgen, Inc. (AMGN)’s Positive Earnings
VIVUS, Inc. (NASDAQ:VVUS), which sells the obesity drug Qsymia, has appointed Anthony Zook to serve as its CEO.
Amgen, Inc. (AMGN), QUALCOMM, Inc. (QCOM): Investing in Growth Stocks — With Ease
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you.
Amgen, Inc. (AMGN), Gilead Sciences, Inc. (GILD): Great Pipelines, Unimpressive Fundamentals
Biotechnology medicine manipulates the genetic material of living organisms to produce pharmaceuticals, which in many instances are designed to combat diseases once considered...
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN): Will This Biotech Bidding War Lead You to Larger Gains?
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) added 3% to its one-month 60% gains on Monday because of continued speculation of a buyout.
Amgen, Inc. (AMGN), Celgene Corporation (CELG): Is Big Biotech Still Growing?
The first half of 2013 has seen remarkable growth in the biotech sector, with the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) up >40% YTD. The industry continues to...
Onyx Pharmaceuticals, Inc. (ONXX), Amgen, Inc. (AMGN): Why Getting Rich Quick Doesn’t (Always) Pay
We have a bona fide biotech soap opera going on these days. Spurned love. Possible romance. Disgruntled suitor. And, of course, the unknown villain.
Amgen, Inc. (AMGN)’s Acquisition Ambition Leads Biotechs’ Rise
Biotech's the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling up or down by significant amounts...
Google Inc (GOOG), Xerox Corporation (XRX) – Wall Street’s Secret Weapon: Women
Times have changed, and women are stepping in to close the gender gap in corporate America.
Celgene Corporation (CELG): Expanding Labels to Expand Margins
In an industry where buyouts are commonplace and small-cap biotechs burn through cash rapidly, optimizing operating cash flow can be essential to a company's financial health.
Four Potential Suitors for Onyx Pharmaceuticals, Inc. (ONXX)
The "people familiar with the matter" are out in full force spouting off about who's bidding for Onyx Pharmaceuticals, Inc.
Merck & Co., Inc. (MRK)’s Late-Stage Breakdown
The Food and Drug Administration cancelled an advisory meeting planned for Merck & Co., Inc. (NYSE:MRK)’s post-surgery drug sugammadex.
A Look at Novartis AG (ADR) (NVS)’ Second Quarter
The story of the second quarter for Novartis AG (ADR) (NYSE:NVS) offered mixed results for investors. The company's net sales were up 1%, and EPS was down 6% year over year.
Onyx Pharmaceuticals, Inc. (ONXX), Alexion Pharmaceuticals, Inc. (ALXN): 3 Biotechs That Could Be Bought Out This Year
Chances are that a few biotech companies will be scooped up by larger players over the coming months.
Amgen, Inc. (AMGN), Hospira, Inc. (HSP): How Valuable Is a Cheaper Treatment for Arthritis?
Arthritis biologics like Remicade, Enbrel, and Humira are pricy drugs that many of the 50 million American arthritis patients – and hundreds of millions of patients worldwide...
